Experts support continued use of Aranesp in certain kidney patients

10/18/2010 | Bloomberg

An FDA advisory panel voted 15-1 for continued use of Amgen's Aranesp in nondialysis patients with chronic kidney disease. The panel also voted 9-5 against lowering dosing for patients with blood hemoglobin levels less than 9 grams per deciliter. The advisers recommended further studies to determine the ideal dosing and to identify which patients benefit from Aranesp.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ